Biotech - EMTIN PEPTIDES for NEURO DEGENERATIVE DISEASE
I have been waiting to see if this would break the 36c - 38 range and it appears to have done so today, though the day is not yet finished, volumes looking good. ST Target around 60c which would put it on a market cap of around $85m which is achievable in my view. (143m SOI)
It has also recently shown that ETINB significantly reduced some biomarkers associated with severe COVID 19 and was safe and well tolerated.
Mitsubishi doing their manufacturing
Paul Rennie from Paradigm was been appointed Chairman in June.
Phase 1 Ocular glaucoma study in patients planned for 2H 2021 with WA based research organisation - so so far uninhibited by COVID
